Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Rosen

Showing results (11-20 of 207) with videos related to

Pageof 21
Sort By:
Current Topics in Medicinal Chemistry|July 18, 2006
Hsp90: a novel target for cancer therapyDavid B Solit, Neal Rosen
Chinese Journal of Cancer|January 4, 2011
Targeted cancer therapiesLi Yan, Neal Rosen, Carlos Arteaga
Nature Medicine|November 9, 2013
Tumor adaptation and resistance to RAF inhibitorsPiro Lito, Neal Rosen, David B Solit
Seminars in Oncology|October 23, 2003
Hsp90 as a therapeutic target in prostate cancerDavid B Solit, Howard I Scher, Neal Rosen
Annals of the New York Academy of Sciences|May 22, 2007
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stressPaul Workman, Francis Burrows, Len Neckers, et al.
Ferroptosis and Oxidative Stress|December 29, 2025
Targeting mTORC1 to promote ferroptosis and apoptosis in endometrial cancer with PI3K-Akt-mTOR pathway mutationYingying Hu, Pei Liu, Neal Rosen, et al.
The Journal of Organic Chemistry|April 24, 2004
General method for the synthesis of 8-arylsulfanyl adenine derivativesHuazhong He, Laura Llauger, Neal Rosen, et al.
Cancer Discovery|July 13, 2013
ERK pathway inhibitors: how low should we go?Moriah H Nissan, Neal Rosen, David B Solit
Chemistry & Biology|August 2, 2003
Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFRHenri Huezo, Maria Vilenchik, Neal Rosen, et al.
Cancer Cell|December 18, 2014
Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouragedPaul B Chapman, David B Solit, Neal Rosen
Pageof 21

Showing results (11-20 of 207) with videos related to

Sort By:
Pageof 21
Current Topics in Medicinal Chemistry|July 18, 2006
Hsp90: a novel target for cancer therapyDavid B Solit, Neal Rosen
Chinese Journal of Cancer|January 4, 2011
Targeted cancer therapiesLi Yan, Neal Rosen, Carlos Arteaga
Nature Medicine|November 9, 2013
Tumor adaptation and resistance to RAF inhibitorsPiro Lito, Neal Rosen, David B Solit
Seminars in Oncology|October 23, 2003
Hsp90 as a therapeutic target in prostate cancerDavid B Solit, Howard I Scher, Neal Rosen
Annals of the New York Academy of Sciences|May 22, 2007
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stressPaul Workman, Francis Burrows, Len Neckers, et al.
Ferroptosis and Oxidative Stress|December 29, 2025
Targeting mTORC1 to promote ferroptosis and apoptosis in endometrial cancer with PI3K-Akt-mTOR pathway mutationYingying Hu, Pei Liu, Neal Rosen, et al.
The Journal of Organic Chemistry|April 24, 2004
General method for the synthesis of 8-arylsulfanyl adenine derivativesHuazhong He, Laura Llauger, Neal Rosen, et al.
Cancer Discovery|July 13, 2013
ERK pathway inhibitors: how low should we go?Moriah H Nissan, Neal Rosen, David B Solit
Chemistry & Biology|August 2, 2003
Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFRHenri Huezo, Maria Vilenchik, Neal Rosen, et al.
Cancer Cell|December 18, 2014
Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouragedPaul B Chapman, David B Solit, Neal Rosen
Pageof 21